STAAR SURGICAL COMPANY

NASDAQ: STAA (STAAR Surgical Company)

Last update: 16 Sep, 8:44PM

27.23

-0.44 (-1.59%)

Previous Close 27.67
Open 27.57
Volume 863,332
Avg. Volume (3M) 1,574,314
Market Cap 1,349,328,128
Price / Earnings (Forward) 62.50
Price / Sales 6.03
Price / Book 4.02
52 Weeks Range
13.50 (-50%) — 38.60 (41%)
Earnings Date 29 Oct 2025
Profit Margin -25.46%
Operating Margin (TTM) -81.43%
Diluted EPS (TTM) -1.44
Quarterly Revenue Growth (YOY) -44.90%
Quarterly Earnings Growth (YOY) 107.20%
Total Debt/Equity (MRQ) 10.48%
Current Ratio (MRQ) 4.78
Operating Cash Flow (TTM) -11.69 M
Levered Free Cash Flow (TTM) 10.73 M
Return on Assets (TTM) -5.90%
Return on Equity (TTM) -19.14%

Market Trend

Short Term Medium Term
Industry Medical Instruments & Supplies (US) Mixed Mixed
Medical Instruments & Supplies (Global) Mixed Bearish
Stock STAAR Surgical Company Bullish Bearish

AIStockmoo Score

0.4
Analyst Consensus 1.5
Insider Activity NA
Price Volatility -2.0
Technical Moving Averages 2.5
Technical Oscillators -0.5
Average 0.38

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
STAA 1 B - - 4.02
MMSI 5 B - 41.98 3.19
LMAT 2 B 0.80% 46.52 5.42
ATRC 2 B - - 3.77
AZTA 1 B - - 0.790
PLSE 1 B - - 12.23

Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of sales are generated from the ophthalmic surgical product segment.

Sector Healthcare
Industry Medical Instruments & Supplies
Investment Style Small Growth
% Held by Insiders 0.64%
% Held by Institutions 109.43%

Ownership

Name Date Shares Held
Resona Asset Management Co.,Ltd. 30 Jun 2025 2,421,836
Yunqi Capital Ltd 30 Jun 2025 2,411,288
52 Weeks Range
13.50 (-50%) — 38.60 (41%)
Price Target Range
18.00 (-33%) — 28.00 (2%)
High 28.00 (Canaccord Genuity, 2.83%) Hold
28.00 (Stifel, 2.83%) Hold
28.00 (Sidoti & Co., 2.83%) Hold
Median 28.00 (2.83%)
Low 18.00 (Mizuho, -33.90%) Hold
Average 25.50 (-6.35%)
Total 4 Hold
Avg. Price @ Call 24.49
Firm Date Target Price Call Price @ Call
Stifel 07 Aug 2025 28.00 (2.83%) Hold 26.95
Canaccord Genuity 06 Aug 2025 28.00 (2.83%) Hold 26.90
Sidoti & Co. 05 Aug 2025 28.00 (2.83%) Hold 27.02
Mizuho 16 Jul 2025 18.00 (-33.90%) Hold 17.09

No data within this time range.

Date Type Details
06 Oct 2025 Announcement Broadwood Partners Issues Letter to STAAR Surgical’s Board Questioning Its Judgment in Proposed Sale to Alcon
06 Oct 2025 Announcement STAAR Surgical: Independent Industry Analysts Recognize Merits of Alcon Merger, the Value It Provides, and the Downside Risks Facing STAAR on Standalone Basis
06 Oct 2025 Announcement STAAR Surgical Addresses Broadwood Partners’ Flawed, Misleading, and Misinformed Claims
03 Oct 2025 Announcement Broadwood Partners Publishes Presentation Detailing Opposition to STAAR Surgical’s Sale to Alcon
30 Sep 2025 Announcement Alcon and STAAR Surgical Announce Expiration of Hart-Scott-Rodino Waiting Period for Alcon’s Acquisition of STAAR
26 Sep 2025 Announcement STAAR Surgical Publishes Presentation Highlighting Compelling, Certain Cash Value Offered by Alcon Merger and Meaningful Downside Risks if Alcon Merger is not Approved
24 Sep 2025 Announcement Broadwood Partners Files Definitive Proxy Statement Soliciting STAAR Surgical Stockholders to Vote “AGAINST” Proposed Acquisition by Alcon
22 Sep 2025 Announcement STAAR Surgical Announces Expiration of “Window Shop” Period; No Competing Acquisition Proposals Received
22 Sep 2025 Announcement Yunqi Capital, 5.1% Holder and One of STAAR Surgical Company’s Largest Shareholders, Announces Intention to Vote Against the Proposed Sale to Alcon
16 Sep 2025 Announcement STAAR Surgical Board of Directors Unanimously Believes Alcon Merger Maximizes Value for STAAR Stockholders
02 Sep 2025 Announcement STAAR Surgical Reiterates Compelling, Premium Cash Value Provided by Alcon Merger
05 Aug 2025 Announcement STAA Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of STAAR Surgical to Alcon
05 Aug 2025 Announcement Alcon Agrees to Acquire STAAR Surgical
31 Jul 2025 Announcement STAAR Surgical to Host Second Quarter 2025 Earnings Conference Call and Webcast on August 6, 2025
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2025 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria